扎斯塔普拉赞的体外代谢和运输特征
Min Seo Lee1, Jihoon Lee2, Minyoung Pang3
1College of Pharmacy and BK21 Four-Sponsored Advanced Program for SmartPharma Leaders, The Catholic University of Korea, Bucheon 14662, Republic of Korea.
Pharmaceutics
|June 27, 2024
概括
扎斯塔普拉桑 (JP-1366) 是由药物代谢酶,主要是CYP3A4 / 3A5广泛代谢,影响其药理动力学. 药物运输体对斯塔普拉桑的吸收,分发和分泌的影响很小.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药物新陈代谢 药物新陈代谢
- 胃肠病学 胃肠病学
背景情况:
- 扎斯塔普拉桑 (JP-1366) 是一种新型竞争性酸阻塞剂,用于治疗侵蚀性食道炎.
- 了解JP-1366的代谢途径和转运体相互作用对于预测其临床药理动力学至关重要.
研究的目的:
- 调查代谢稳定性,并确定主要的药物代谢酶和运输体,涉及到施塔普拉桑 (JP-1366) 的处置.
主要方法:
- 将JP-1366与来自不同物种 (人,小鼠,老鼠,狗,) 的肝细胞进行化,以评估代谢稳定性和识别代谢物.
- 使用CYP抗体进行P450 (CYP) 查和免疫抑制测定,以确定参与新陈代谢的特定CYP.
- 评估JP-1366及其活性代谢物M1作为主要药物载体 (例如OCT,OAT,OATP,MATE,P-gp,BCRP) 的基质.
主要成果:
- JP-1366在人类,小鼠和狗肝细胞中表现出高新陈代谢,18种I阶段和5种II阶段代谢物被确定.
- 鉴定出CYP3A4和CYP3A5是负责JP-1366代谢的主要酶,其它CYP则起轻微的作用.
- 对于大多数测试的药物载体,JP-1366及其活性代谢物M1不是基质,除了M1对P-gp具有基质特异性.
结论:
- 药物代谢酶,特别是CYP3A4/3A5,在确定斯塔普拉赞的药理动力学方面发挥着重要作用.
- 药物运输体可能对斯塔普拉桑的吸收,分布和分泌产生最小的影响.
相关概念视频
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
38
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
38
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
120
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
120
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
196
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
196
Factors Affecting Drug Biotransformation: Physicochemical and Chemical Properties of Drugs
230
A drug's physicochemical properties fundamentally influence its metabolism. For instance, a drug's molecular size and shape critically determine its interaction with enzymes and transporters — larger drugs may face difficulty reaching enzyme active sites, altering their metabolic pathways. The pKa of a drug, which establishes its ionization state, can impact its solubility and absorption, thereby influencing metabolism.
The drug's acidity or basicity is essential in...
The drug's acidity or basicity is essential in...
230
Carrier-Mediated Transport
335
Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
335
Factors Influencing Drug Absorption: Presystemic Elimination
208
The pharmacokinetic journey of oral drugs begins with a crucial first pass through the hepatic portal system, called the first-pass effect. This first pass significantly impacts bioavailability — the proportion of a drug that enters systemic circulation and is available for therapeutic action. The primary route sees the drug absorbed by intestinal membranes and then shunted to the liver via the hepatic portal vein. Here, pre-systemic elimination occurs as drugs face metabolism or biliary...
208


